{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:47:24Z","timestamp":1789015644876,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.metabol.2012.08.024","type":"journal-article","created":{"date-parts":[[2012,9,26]],"date-time":"2012-09-26T04:59:01Z","timestamp":1348635541000},"page":"S30-S33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"S1","title":["Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention"],"prefix":"10.1016","volume":"62","author":[{"given":"Theodore B.","family":"VanItallie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2012.08.024_bb0005","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1212\/WNL.0b013e3182563bbe","article-title":"Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease","volume":"78","author":"Knopman","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.metabol.2012.08.024_bb0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","article-title":"Staging of Alzheimer's disease-related neurofibrillary changes","volume":"16","author":"Braak","year":"1995","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.metabol.2012.08.024_bb0015","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jalz.2011.02.004","article-title":"Alzheimer Association report 2011: Alzheimer's disease facts and figures","volume":"7","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.metabol.2012.08.024_bb0020","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.neurobiolaging.2003.12.023","article-title":"ApoE genotype accounts for the vast majority of risk and AD pathology","volume":"25","author":"Raber","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.metabol.2012.08.024_bb0025","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1074\/jbc.M111.295451","article-title":"Apolipoprotein E promotes \u03b2-amyloid trafficking and degradation by modulating microglial cholesterol levels","volume":"287","author":"Lee","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2012.08.024_bb0030","author":"Cramer"},{"issue":"6012","key":"10.1016\/j.metabol.2012.08.024_bb0035","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1126\/science.1197623","article-title":"Decreased clearance of CNS beta-amyloid in Alzheimer's disease","volume":"330","author":"Mawuenyega","year":"2010","journal-title":"Science"},{"issue":"134","key":"10.1016\/j.metabol.2012.08.024_bb0040","doi-asserted-by":"crossref","first-page":"134ed4","DOI":"10.1126\/scitranslmed.3004274","article-title":"APOE \u03b54 status and traumatic brain injury on the gridiron or the battlefield","volume":"4","author":"Gandy","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.metabol.2012.08.024_bb0045","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/archneurol.2011.167","article-title":"The dynamics of cortical and hippocampal atrophy in Alzheimer disease","volume":"68","author":"Subuncu","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.metabol.2012.08.024_bb0050","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1212\/WNL.0b013e3182166e96","article-title":"Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults","volume":"76","author":"Dickerson","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.metabol.2012.08.024_bb0055","doi-asserted-by":"crossref","first-page":"825.e25","DOI":"10.1016\/j.neurobiolaging.2011.05.018","article-title":"Structural MRI changes detectable up to ten years before clinical Alzheimer's disease","volume":"33","author":"Tondelli","year":"2012","journal-title":"Neurobiol Aging"},{"issue":"7","key":"10.1016\/j.metabol.2012.08.024_bb0060","doi-asserted-by":"crossref","first-page":"e22506","DOI":"10.1371\/journal.pone.0022506","article-title":"Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer's disease","volume":"6","author":"Westman","year":"2011","journal-title":"PloS ONE"},{"issue":"Suppl. 3","key":"10.1016\/j.metabol.2012.08.024_bb0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-0002","article-title":"Presence of ApoE \u03b54 allele associated with thinner frontal cortex in middle age","volume":"26","author":"Fennema-Notestine","year":"2011","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"10.1016\/j.metabol.2012.08.024_bb0070","doi-asserted-by":"crossref","first-page":"2325.e17","DOI":"10.1016\/j.neurobiolaging.2011.01.001","article-title":"Structural brain changes in normal individuals with a maternal history of Alzheimer's","volume":"32","author":"Berti","year":"2011","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.metabol.2012.08.024_bb0075","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-005-1762-7","article-title":"Brain glucose metabolism in the early and specific diagnosis of Alzhiemer's disease. FDG-PET studies in MCI and AD.","volume":"32","author":"Mosconi","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.metabol.2012.08.024_bb0080","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2012.08.024_bb0085","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.febslet.2007.12.035","article-title":"Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease","volume":"582","author":"Liu","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1016\/j.metabol.2012.08.024_bb0090","series-title":"Handbook of imaging the Alzheimer brain","first-page":"219","article-title":"A tale of two tracers: glucose metabolism and amyloid positron emission tomography imaging in Alzheimer's disease","author":"Mosconi","year":"2011"},{"key":"10.1016\/j.metabol.2012.08.024_bb0095","doi-asserted-by":"crossref","first-page":"10966","DOI":"10.1073\/pnas.191044198","article-title":"Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose\/positron-emission tomography (FDG\/PET)","volume":"98","author":"de Leon","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.metabol.2012.08.024_bb0100","doi-asserted-by":"crossref","first-page":"19067","DOI":"10.1073\/pnas.0705036104","article-title":"Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism","volume":"104","author":"Mosconi","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.metabol.2012.08.024_bb0105","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.22608","article-title":"Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data","volume":"70","author":"Vlassenko","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.metabol.2012.08.024_bb0110","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/archneurol.2011.150","article-title":"Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease","volume":"68","author":"Fleisher","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.metabol.2012.08.024_bb0115","article-title":"Apolipoprotein E \u03b54 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease","author":"Fleisher","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.metabol.2012.08.024_bb0120","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/00002093-199809000-00011","article-title":"Role of familial factors in late-onset Alzheimer disease as a function of age","volume":"12","author":"Wu","year":"1998","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.metabol.2012.08.024_bb0125","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1001\/archneurol.2011.208","article-title":"Role of family history for Alzheimer biomarker abnormalities in the adult children study","volume":"68","author":"Xiong","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.metabol.2012.08.024_bb0130","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3122\/jabfm.2012.03.100183","article-title":"Guidelines for the management of cognitive and behavioral problems in dementia","volume":"25","author":"Sadowsky","year":"2012","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.metabol.2012.08.024_bb0135","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/B978-0-12-385883-2.00005-9","article-title":"Biology of mitochondria in neurodegenerative diseases","volume":"107","author":"Martin","year":"2012","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.metabol.2012.08.024_bb0140","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1523\/JNEUROSCI.0465-12.2012","article-title":"Impaired short-term plasticity in mossy fiber synapses caused by mitochondrial dysfunction of dentate granule cells is the earliest synaptic deficit in a mouse model of Alzheimer's disease","volume":"32","author":"Lee","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.metabol.2012.08.024_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/s13380-011-0011-8","article-title":"Mitochondrial bioenergetics is defective in presymptomatic Tg2576 AD mice","volume":"2","author":"Varghese","year":"2011","journal-title":"Transl Neurosci"},{"key":"10.1016\/j.metabol.2012.08.024_bb0150","doi-asserted-by":"crossref","first-page":"14670","DOI":"10.1073\/pnas.0903563106","article-title":"Mitochondrial bioenergetics deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease","volume":"106","author":"Yao","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.metabol.2012.08.024_bb0155","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JAD-2010-100129","article-title":"Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE \u03b54 allele, the major late-onset Alzheimer's susceptibility gene","volume":"22","author":"Valla","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.metabol.2012.08.024_bb0160","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/biof.37","article-title":"Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E","volume":"35","author":"Fan","year":"2009","journal-title":"Biofactors"},{"key":"10.1016\/j.metabol.2012.08.024_bb0165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/iub.590","article-title":"The mitochondrial permeability transition pore provides a key to the diagnosis and treatment of traumatic brain injury","volume":"64","author":"Veech","year":"2012","journal-title":"IUBMB Life"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049512003289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049512003289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T03:58:28Z","timestamp":1758427108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049512003289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":33,"alternative-id":["S0026049512003289"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2012.08.024","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2012.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}